Kaixiu Wang, Wei Jiang, Chao Cheng, Yusheng Li* and Min Tu* Pages 1312 - 1316 ( 5 )
Background: Osteosarcoma (OS) is a common bone malignant tumor, which is the eighth leading form of pediatric cancer. Despite the modern chemotherapeutic development of OS, a number of patients with OS have a high risk of lung metastasis and local relapse after chemotherapy.
Objective: This review study focused on the role of long non coding RNAs (lncRNAs) in OS progression, and presented update reports on OS treatment by targeting specific lncRNAs.
Method: We have acquired information on OS and lncRNAs from scientific databases like google scholar, pubmed and scopus, and reviewed for this study.
Results: The lncRNAs regulate a number of biological processes, and abnormal expression of lncRNAs could play role in many cancers and other human diseases. Interestingly, some lncRNAs can act as oncogenes, while some act as tumor suppressor genes. A number of studies revealed that targeting the specific lncRNAs by RNA interferance technology may provide a novel therapeutic strategy in the treatment of OS.
Conclusion: LncRNAs could be a promising biomarker and might be a potential therapeutic target in OS patients.
Cancer therapeutics, diagnostic markers, long non coding RNA, osteosarcoma, pathological aspects, abnormal expression.
Department of gynaecology, Second People's Hospital of Jingmen, Jingmen, HuBei 448000, Department of Bone and Joint, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, Shenzhen, Guangdong 518020, Department of Orthopaedics, Central Hospital of Yiyang, Yiyang, Hunan 413000, Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan 410078, Department of Orthopaedics, Second People's Hospital of Jingmen, Jingmen, HuBei 448000